Abstract: The invention relates to methods of treatment of a solid tumor in a patient in need thereof, comprising administering to the patient: (i) an effective amount of engineered immune cells originating from a donor expressing at their cell surface a Chimeric Antigen Receptor (CAR) directed against Fibroblast Activation Protein (FAP), and (ii) an effective amount of an immunotherapy treatment that elicits an immune response in the patient.

Abstract: Systems, methods, and apparatuses for isolating information from a cloud services provider hosting an enterprise application software, using a distributed ledger. For example, according to one embodiment there is a system having at least a processor and a memory therein executing within a host organization to host an enterprise application software for an enterprise, receive information input from a customer of the enterprise at a user interface for the enterprise application software, transfer the customer-provided information to a distributed ledger accessible to the system, receive information input from the enterprise at an enterprise interface for the enterprise application software, transfer the enterprise-provided information to the distributed ledger accessible to the system, but maintain no copy of the customer-provided information nor copy of the enterprise-provided information in a permanent store accessible to the system and the host organization.

Abstract: The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.